atenolol has been researched along with moxonidine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Elliott, HL; MacPhee, G; Panfilov, V; Reid, JL | 1 |
| Robles, NR | 1 |
| Kaaja, R; Manhem, K; Tuomilehto, J | 1 |
| Antikainen, R; Erkkola, R; Kaaja, R; Katzman, P; Kibarskis, A; Kujala, S; Manhem, K; Tuomilehto, J; Ylihärsilä, H | 1 |
| Hausberg, M; Hillebrand, U; Kisters, K | 1 |
| Antikainen, RL; Ebeling, PE; Erkkola, RU; Kaaja, RJ; Katzman, P; Kibarskis, A; Manhem, K; Pöyhönen-Alho, MK; Tuomilehto, JO | 1 |
| Kaaja, RJ; Kujala, SM; Pöyhönen-Alho, M | 1 |
1 review(s) available for atenolol and moxonidine
| Article | Year |
|---|---|
Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.
Topics: Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Clonidine; Humans; Hypertension; Imidazoles; Imidazoline Receptors; Oxazoles; Placebos; Receptors, Adrenergic; Receptors, Drug; Reference Values; Rilmenidine | 1995 |
4 trial(s) available for atenolol and moxonidine
| Article | Year |
|---|---|
Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist.
Topics: Antihypertensive Agents; Atenolol; Blood Glucose; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Imidazoline Receptors; Insulin; Middle Aged; Postmenopause; Prospective Studies; Receptors, Drug; Sympatholytics | 2004 |
Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Finland; Humans; Hypertension; Imidazoles; Imidazoline Receptors; Insulin; Insulin Resistance; Lithuania; Middle Aged; Obesity; Postmenopause; Sweden; Sympatholytics | 2007 |
Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women.
Topics: Adiponectin; Antihypertensive Agents; Atenolol; C-Reactive Protein; Double-Blind Method; Female; Finland; Humans; Hypertension; Imidazoles; Inflammation; Insulin Resistance; Interleukin-6; Lithuania; Middle Aged; Overweight; Postmenopause; Prospective Studies; Receptors, Tumor Necrosis Factor, Type II; Sweden; Sympathetic Nervous System; Tumor Necrosis Factor-alpha | 2008 |
Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women.
Topics: Atenolol; Blood Pressure; Body Mass Index; Double-Blind Method; Drug Monitoring; Female; Hot Flashes; Humans; Hypertension; Imidazoles; Insulin Resistance; Middle Aged; Postmenopause; Sleep Initiation and Maintenance Disorders; Sympathetic Nervous System; Sympatholytics; Treatment Outcome | 2014 |
8 other study(ies) available for atenolol and moxonidine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
[New central agents in the treatment of arterial hypertension].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Adult; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Clonidine; Diabetes Complications; Humans; Hypertension; Imidazoles; Nifedipine; Oxazoles; Renin-Angiotensin System; Reserpine; Rilmenidine; Risk Factors; Sympathetic Nervous System; Vasodilator Agents | 1999 |
Addressing the relationship between sympathetic activity and inflammation.
Topics: Antihypertensive Agents; Atenolol; C-Reactive Protein; Female; Humans; Hypertension; Imidazoles; Inflammation; Insulin Resistance; Middle Aged; Overweight; Sympathetic Nervous System; Tumor Necrosis Factor-alpha | 2008 |